Predictive Oncology Announces Closing of $4.1 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
26 janv. 2021 21h00 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology Announces $4.1 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
22 janv. 2021 08h00 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology Announces Closing of $2.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
21 janv. 2021 17h25 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
19 janv. 2021 08h00 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology Reports That Its Wholly Owned Subsidiary, TumorGenesis, Has Sold Media to Two Top Research Medical Centers
14 janv. 2021 08h30 HE
|
Predictive Oncology Inc.
EAGAN, Minn., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug...
Predictive Oncology Announces Closing of $3.074 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
12 janv. 2021 17h15 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology Announces $3,074,007 Registered Direct Offering Priced At-The-Market under Nasdaq Rules
08 janv. 2021 09h00 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial...
Predictive Oncology’s Wholly Owned Subsidiary Helomics completes integration of Quantitative Medicine
06 janv. 2021 08h30 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug...
Predictive Oncology Hires Investor Relations Firm
05 janv. 2021 08h30 HE
|
Predictive Oncology Inc.
MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug...
Predictive Oncology Announces Cancellation of Special Meeting in December 2020
29 déc. 2020 17h15 HE
|
Predictive Oncology Inc.
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) (the “Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine...